Summary
The immunological cardiovascular diseases are a very diverse group of clinical entities that generally are of either unknown aetiology or of unproven pathophysiology. Most of the conditions with a proven, or strongly suspected, aetiology are caused by infections, with the best examples being acute rheumatic fever and Lyme disease. However, even with these diseases, the primary pathophysiological mechanisms have not been irrefutably established. In addition to the importance of infectious agents in the immunological cardiovascular diseases, other factors have been identified that are associated with or modify these diseases. These factors include age, genetic background and coexisting inflammatory diseases.
The proposed immunological mechanisms important in the immunological cardiovascular diseases include: (a) immune mimicry, in which antigens of an infectious agent crossreact with self antigens; (b) modification of self antigens by infections or other inflammatory processes; (c) introduction of self antigens to the immune system following a traumatic or inflammatory event; and (d) dysregulation of an autoimmune response. The immunological effector mechanisms include: (a) passive deposition of immunoglobulin or immune complexes in cardiovascular tissues with resulting inflammation; (b) autoantibodies that damage the cardiovascular system directly or indirectly; and (c) cell-mediated immune responses to antigens within the cardiovascular system.
The clinical diagnosis of the immunological cardiovascular diseases is facilitated by clinical criteria and by selective laboratory tests in certain diseases. Laboratory tests, other than histology, do not usually provide definitive answers but serve to confirm suspected diagnoses. The vague, often systemic, symptoms associated with many of the disorders add to the clinical confusion of diagnosis.
Despite the lack of clearcut aetiologies, the classification of these diseases does facilitate therapeutic decision making. This is particularly important since the prognosis of some of these conditions, such as acute rheumatic fever, Lyme disease, Wegener’s granulomatosis, systemic necrotising vasculitis and temporal arteritis, is significantly improved by treatment. Classification schemes for vasculitis remain primarily descriptive, but are useful for dividing the entities into categories with similar response to treatment. Significant progress and improvement in the treatment of the immunological cardiovascular disorders await better definition of the aetiologies and primary pathophysiological mechanisms involved.
Article PDF
Similar content being viewed by others
References
Parrillo JE, Fauci AS. Immunological diseases of the cardiovascular system. In: Lockey RF, Bukantz SC, editors. Principles of Immunology and Allergy. Philadelphia: Saunders, 1987: 271–87
Shimizu Y, Newman W, Tanaka Y et al. Lymphocyte interactions with endothelial cells. Immunol Today 1992; 13: 106–12
Zimmerman GA, Prescott SM, McIntyre A. Endothelial cell interactions with granulocytes: tethering and signalling molecules. Immunol Today 1992; 113: 93–9
Markowitz M, Kaplan EL. Reappearance of rheumatic fever. Adv Pediatr 1989; 361: 39–65
Stollerman GH. Rheumatic fever. In: Kelley WN, Harris ED, Ruddy S, et al., editors. Textbook of Rheumatology. 2nd ed. Philadelphia: Saunders, 1985: 1277–93
Husby G, Van de Rijn I, Zabriskie JB, et al. Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J Exp Med 1976; 144: 1094–110
Abe J, Forrester J, Nakahara T, et al. Selective stimulation of human T-cells with streptococcal erythrogenic toxins A and B. J Immunol 1991; 146: 3747–50
Patarroyo ME, Winchester RJ, Vejerano A, et al. Association of a B-cell alloantigen with susceptibility to rheumatic fever. Nature 1979; 278: 173–4
Jones criteria (revised) for guidance in the diagnosis of rheumatic fever. Circulation 1965; 32: 664–8
Barnert AL, Jerry EE, Persellin RH. Acute rheumatic fever in adults. JAMA 1975; 232: 925–8
Perry BC. Erythema marginatum. Arch Dis Child 1937; 12: 233–8
Beachey EH, Stollerman GH, Johnson RH, et al. Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein. J Exp Med 1979; 150: 862–77
Bisno AL. Rheumatic fever. In: Kelly WN, Harris ED, Ruddy S, et al., editors. Textbook of rheumatology. 4th ed. Philadelphia: Saunders, 1993: 1209–23
Bisno AL. The resurgence of acute rheumatic fever in the U.S. Annu Rev Med 1990; 41: 391–2
Vasiljevic JD, Kanjuh V, Seferovic P. The incidence of myocarditis in endomyocardial biopsy samples from patients with congestive heart failure. Am Heart J 1990; 120: 1370–7
Lie JT. Myocarditis and endomyocardial biopsy in unexplained heart failure: a diagnosis in search of a disease. Ann Intern Med 1988; 109: 525–8
Bowles NE, Rose ML, Taylor P, et al. End-stage dilated cardiomyopathy. Persistence of enterovirus RNA in myocardium at cardiac transplantation and lack of immune response. Circulation 1989; 80: 1128–36
Hypiä T. Etiological diagnosis of viral heart disease. Scand J Infect Dis 1993; 88 (Suppl.): 25–31
McManus BM, Kendolph R. Evolving concepts of cause, consequence and control in myocarditis. Curr Opin Cardiol 1991; 6: 418–27
Woodruff JF. Viral myocarditis: a review. Am J Pathol 1980; 101: 427–80
Maisch B, Trostel-Soeder R, Stechmesser F, et al. Diagnostic relevance of humoral and cell-mediated immune reactions in patients with acute viral myocarditis. Clin Exp Immunol 1982; 48: 533–45
Hufnagel G, Maisch B. Expression of MHC class I and II antigens and the IL-2 receptor in rejection, myocarditis and dilated cardiomyopathy. Eur Heart J 1991; 12: 137–40
Kühl U, Daun B, Seeberg B, et al. Dilated cardiomyopathy — a chronic myocarditis? Immunohistological characterization of lymphocytic infiltrates. Herz 1992; 17: 97–106
Hergstenberg C, Rose ML, Olsen MCJ, et al. Immune resonse to the endothelium in myocarditis, dilated cardiomyopathy and rejection after heart transplantation. Eur Heart J 1991; 12: 144–6
Sanderson JE, Koech D, Iha D, et al. T-lymphocyte subsets in idiopathic dilated cardiomyopathy. Am J Cardiol 1985; 55: 755–8
Maze SS, Adolph RJ. Myocarditis: unresolved issues in diagnosis and treatment. Clin Cardiol 1990; 13: 69–79
Maisch B, Herzum M, Schonian U. Immunomodulating factors and immunosuppressive drugs in the therapy of myocarditis. Scand J Inf Dis 1993; 88(S): 149–62
Rothfield N. Clinical features of systemic lupus erythematosus. In: Kelley WN, Harris ED, Ruddy S, et al., editors. Textbook of Rheumatology. 2nd ed. Philadelphia: Saunders, 1985: 1087–8
Hochberg MC, Dorsch CA, Feinglass EJ, et al. Survivorship in SLE: effect of antibody to extractable nuclear antigen. Arth Rheum 1981; 24: 54–9
Lockshin MD, Bonfa E, Elkon K, Druzin ML. Neonatal lupus risk to newborns of mothers with systemic lupus erythematosus. Arth Rheum 1988; 31: 697–701
Straaton KV, Chatham WW, Reveille JD, et al. Clinically significant valvular heart disease in systemic lupus erythematosus. Am J Med 1988; 85: 645
Chartash EK, Lang DM, Paget SA, et al. Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med 1989; 86: 467–14
Lockshin MD. Which patients with antiphospholipid antibody should be treated and how? Rheum Dis Clin N Am 1993; 19: 235–47
Lockshin MD. Antiphospholipid antibody and antiphospholipid syndrome. Curr Opin Rheumatol 1991; 3: 797–802
Lockshim MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989; 160: 439–43
Qamar T, Levy RA, Sammaritano L. Characteristics of high-titer IgG antiphospholipid antibody in systemic lupus erythematosus patients with and without fetal death. Arth Rheum 1990; 33: 501–4
Steere AC. Lyme disease. N Engl J Med 1989; 321: 586–96
Steere AC, Batsford WP, Weinberg M, et al. Lyme carditis: cardiac abnormalities of Lyme disease. Ann Intern Med 1980; 98: 8
McAlister HF, Klementowica PT, Andrews C, et al. Lyme carditis: an important cause of reversible heart block. Ann Intern Med 1989; 110: 339
Rahn DW, Malawista SE. Lyme disease: recommendations for diagnosis arid treatment. Ann Intern Med 1991; 114: 472–87
Cupps TR, Fauci AS. The vasculitides. In: Smith LH, editor. Major problems in internal medicine. Philadelphia: Saunders, 1981; 21: 1–211
Fauci AS, Haynes B, Katz P. The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med 1978; 89: 660–76
Sergent JS, Lockshin MD, Christin CL, et al. Vasculitis with hepatitis B antigenemia: long-term observations in nine patients. Medicine 1976; 55: 1–18
Kohler PF, Claman HV. Systemic vasculitis. In: Franklin EC, editor. Clinical immunology updates: reviews for physicians. New York: Elsevier, 1981: 293–319
Brasile L, Kremer JM, Clarke JL, Cerilli J. Identification of an autoantibody to vascular endothelial cell-specific antigens in patients with systemic vasculitis. Am J Med 1989; 87: 74–80
Frampton G, Jayne DR, Perry GJ, et al. Autoantibodies to endothelial cells and neutrophil cytoplasmic antigens in systemic vasculitis. Clin Exp Immunol 1990; 82: 227–32
Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991; 64: 5–15
Bloch DA, Micel BA, Hunder GG, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: patients and methods. Arthritis Rheum 1990; 33: 1068–73
Fries JF, Hunder GG, Bloch PA et al. The American College of Rheumatology 1990 criteria for classification of vasculitis: summary. Arthritis Rheum 1990; 33: 1065–7
Guillevin L, Le This Huong Du, Godeau P, et al. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis; a study in 165 patients. Br J Rheumatol 1988; 27: 258–64
Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33: 1094–100
Chaauhan C, Scott DGI, Neuberger J, et al. Churg-Strauss vasculitis and ascaris infection. Ann Rheum Dis 1990; 49: 320–2
Leavitt RY, Fauci AS. Polyangiitis overlap syndrome: classification and prospective clinical experience. Am J Med 1986; 81: 79–84
Dahlberg PJ, Lockhart JM, Overholt EL. Diagnostic studies for systemic necrotizing vasculitis. Arch Intern Med 1989; 149: 161–5
Fauci AS, Katz P, Haynes BF, et al. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979; 301: 235–8
Casato M, Lagana B, Giorgi A, et al. Clinical effects of interferon in patients with idiopathic mixed cryoglobulinemia. Eur J Hematol 1990; 52S: 7–8
Fauci AS, Haynes BF, Katz P, et al. Wegener’s granulomatosis. Ann Intern Med 1983; 98: 76–85
Ferraro G, Meroni PL, Tincani A, et al. Anti-endothelial cell antibodies in patients with Wegener’s granulomatosis and micropolyarteritis. Clin Exp Immunol 1990; 79: 47–53
Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318: 1651–7
Goldschmeding R, van der Schoot CE, ten Bokkel Huinink D, et al. Wegener’s granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest. 1989; 84: 1577–87
Nölle B, Specks U, Lüdemann J, et al. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener’s granulomatosis. Ann Int Med 1989; 111: 28–40
Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 1990; 33: 1101–7
Hoffman GS, Leavitt RY, Kerr GS, et al. The treatment of Wegener’s granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992; 35: 1322–9
Valeriano-Marcet J, Spiera H. Treatment of Wegener’s granulomatosis with sulfamethoxazole-trimethoprim. Arch Intern Med 1991; 151: 1649–52
Rodgers H, Guthrie JA, Brownjohn AM, et al. Microscopic polyarteritis: clinical features and treatment. Postgrad Med J 1989; 65: 515–8
Esnault VL, Ronda N, Jayne DR, et al. Association of ANCA isotype and affinity with disease expression. J Autoimmun 1993; 6: 197–205
Jayne DR, Esnault VL, Lockwood CM. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 1993; 6: 207–19
Huston KA, Hunder GG, Lie JT, et al. Temporal arteritis: a 25-year epidemiologic, clinical and pathologic study. Ann Intern Med 1978; 88: 162–7
Elling P, Olsson A, Elling H. CD8+ T-lymphocyte subset in giant cell arteritis and related disorders. J Rheumatol 1990; 17: 225–7
Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122–8
Rosenfeld SI, Komorsky GS, Klingele TG, et al. Treatment of temporal arteritis with ocular involvement. Am J Med 1986; 80: 143
Hall S, Barr W, Lie JJ, et al. Takayasu arteritis: a study of 32 American patients. Medicine (Baltimore) 1985; 64: 89–99
Naito S, Arakawa K, Saito S, et al. Takayasu’s disease: association with HLA-B5. Tissue Antigens 1978; 12: 143–5
Isonisa I, Numano F, Maezawa J, et al. HLA-BW52 in Takayasu disease. Tissue Antigens 1978; 12: 246–8
Numano F, Isonisa I, Maezawa J, et al. HLA antigens in Takayasu’s disease. Am Heart J 1979; 98: 153–4
Volkman DJ, Mann DL, Fauci AS. Association between Takayasu’s arteritis and a B cell alloantigen in North America. N Engl J Med 1982; 306: 364–5
Cupps TR, Fauci AS. The vasculitides. Philadelphia: Saunders, 1981
Lupi-Herrera E, Sanchez-Torres G, Marcushamer J, et al. Takayasu arteritis: clinical study of 107 cases. Am Heart J 1977; 93: 94
Shelhamer JH, Volkman DJ, Parrillo JE, et al. Takayasu’s arteritis and its therapy. Ann Intern Med 1985; 103: 121–6
Ishikawa K. Survival and morbidity after diagnosis of occlusive thromboarthropathy (Takayasu’s disease). Am J Cardiol 1981; 47: 1026–32
Grossman E, Morag B, Nussinovitch N, et al. Use of Captopril in Takayasu’s arteritis. Arch Int Med 1984; 144: 95
Hricik DE, Browning PJ, Kopetman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney. N Engl J Med 1983; 708: 373
Gibson LE. Cutaneous vasculitis: approach to diagnosis and systemic associations. Mayo Clin Proc 1990; 65: 221–9
Gorevic PB, Kassab HYJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69: 287
Boon BW, Brand A, Bavinck J, et al. Severe leukocytoclastic vasculitis of the skin in a patient with mixed cryoglobulinemia treated with high-dose gammaglobulin intravenously. Arch Dermatol 1988; 124: 1550
Melish ME, Hicks RV. Kawasaki syndrome: clinical features, pathophysiology, etiology, and therapy. J Rheumatol 1990; 17 (24 Suppl.): 2–10
Leung DY, Meissner HC, Fulton DR, et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993; 342: 1585–8
Leung DY. Immunologic aspects of Kawasaki syndrome. J Rheumatol 1990; 17 (24-Suppl.): 15–8
Leung DY, Geha R, Newburger J. Two monokines, interleukin-1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J Exp Med 1986; 164: 1958–72
Leung DY. The potential role of cytokine-mediated vascular endothelial activation in the pathogenesis of Kawasaki disease. Acta Paediatr Jpn 1991; 33: 739–44
Newburger JW, Takahasi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633
Moore PM. Diagnosis and management of isolated angiitis of the central nervous system. Neurology 1989; 39: 167–73
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ledford, D.K. Immunological Aspects of Cardiovascular Diseases. Clin. Immunother. 1, 327–347 (1994). https://doi.org/10.1007/BF03258511
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03258511